Phase 2 Trial of Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus Methotrexate- Cytarabine for Relapsed or Refractory Aggressive Mantle Cell Lymphoma.

The article presents the clinical trial of several antineoplastic agents including rituximab, methotrexate, and cytarabine which treat patients with refractory mantle cell lymphoma (MCL) in the U.S. It notes that toxicity, neutropenic fever, and thrombocytopenia are the side effects of the anticancer agents. Moreover, it emphasizes the effectiveness of chemotherapeutic agents including cyclophosphamide, vincristine, and doxorubicin on treating MCL.